We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Parental woes

24 Oct 2017 By Neil Unmack

The Swiss drugmaker’s troubled eyecare unit performed better in the third quarter, reducing pressure for a quick sale. Its generic business still faces challenges despite beating forecasts. The group’s devotion to its stake in rival Roche, however, remains hard to justify.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)